{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:54:27Z","timestamp":1791888867024,"version":"4.3.4"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thebonejournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.bone.2014.05.016","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T17:46:18Z","timestamp":1401990378000},"page":"46-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":113,"special_numbering":"C","title":["New developments in biological markers of bone metabolism in osteoporosis"],"prefix":"10.1016","volume":"66","author":[{"given":"Patrick","family":"Garnero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2014.05.016_bb0005","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrrheum.2012.86","article-title":"Bone turnover markers: use in osteoporosis","volume":"8","author":"Naylor","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.bone.2014.05.016_bb0010","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1515\/cclm-2011-0614","article-title":"Blood biochemical markers of bone turnover: pre-analytical and technical aspects of sample collection and handling","volume":"50","author":"Lombardi","year":"2012","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.bone.2014.05.016_bb0015","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.clinbiochem.2012.01.022","article-title":"The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis","volume":"45","author":"Szulc","year":"2012","journal-title":"Clin Biochem"},{"key":"10.1016\/j.bone.2014.05.016_bb0020","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00198-006-0296-6","article-title":"The periosteum\u2014a surface for all seasons","volume":"18","author":"Seeman","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.bone.2004.09.004","article-title":"Biochemical markers of bone formation reflect endosteal bone loss in elderly men\u2014MINOS study","volume":"36","author":"Szulc","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.05.016_bb0035","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/jbmr.5650050906","article-title":"Heterogeneity of human bone","volume":"9","author":"Ninomiya","year":"1990","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0040","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00198-011-1892-7","article-title":"The multiple facets of periostin in bone metabolism","volume":"23","author":"Merle","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0045","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/cbin.10219","article-title":"Periostin and transforming factor \u03b2-induced protein (TGF\u03b2Ip) are both expressed by osteoblasts and osteoclasts","author":"Merle","year":"2014","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0050","doi-asserted-by":"crossref","first-page":"35939","DOI":"10.1074\/jbc.M109.060335","article-title":"The matricellular protein periostin is required for SOST inhibition and the anabolic response to mechanical loading and physical activity","volume":"284","author":"Bonnet","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2014.05.016_bb0055","doi-asserted-by":"crossref","first-page":"15048","DOI":"10.1073\/pnas.1203085109","article-title":"Regulation of beta catenin signaling and parathyroid hormone anabolic effects in bone by the matricellular protein periostin","volume":"109","author":"Bonnet","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bone.2014.05.016_bb0060","doi-asserted-by":"crossref","first-page":"e58726","DOI":"10.1371\/journal.pone.0058726","article-title":"Zoledronate effects on systemic and jaw osteopenias in ovariectomized periostin-deficient mice","volume":"8","author":"Bonnet","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2014.05.016_bb0065","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1074\/jbc.M109.051961","article-title":"Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture","volume":"285","author":"Kii","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2014.05.016_bb0070","doi-asserted-by":"crossref","first-page":"13294","DOI":"10.1074\/jbc.M109.088864","article-title":"Interaction between periostin and BMP-1 promotes proteolytic activation of lysyl oxidase","volume":"285","author":"Maruhashi","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2014.05.016_bb0075","first-page":"1167","article-title":"Periostin: novel diagnostic and therapeutic target for cancer","volume":"22","author":"Kudo","year":"2007","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.bone.2014.05.016_bb0080","first-page":"SU0113","article-title":"Periostin: a novel serum marker of cortical bone formation","author":"Bonnet","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0085","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-3893","article-title":"Serum periostin is associated with fracture risk in postmenopausal women: a 7years prospective analysis of the OFELY study","author":"Rousseau","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0090","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.2174\/13894501113149990202","article-title":"Cathepsin K inhibitors: a novel target but promising approach in the treatment of osteoporosis","volume":"14","author":"Helali","year":"2013","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.bone.2014.05.016_bb0095","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1359\/jbmr.2001.16.3.478","article-title":"Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption","volume":"16","author":"Dodds","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0100","doi-asserted-by":"crossref","first-page":"12517","DOI":"10.1074\/jbc.271.21.12517","article-title":"Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification","volume":"271","author":"Bossard","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2014.05.016_bb0105","first-page":"1","article-title":"Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget's disease","volume":"52","author":"Meier","year":"2006","journal-title":"Clin Lab"},{"key":"10.1016\/j.bone.2014.05.016_bb0110","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1186\/ar1461","article-title":"Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction","volume":"7","author":"Skoumal","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bone.2014.05.016_bb0115","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jbspin.2008.01.026","article-title":"Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: effect of TNF alpha antagonist therapy","volume":"75","author":"Wendling","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.bone.2014.05.016_bb0120","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/gme.0b013e3181271873","article-title":"Cathepsin K predicts femoral neck bone mineral density change in non osteoporotic peri- and early postmenopausal women","volume":"15","author":"Prezelj","year":"2008","journal-title":"Menopause"},{"key":"10.1016\/j.bone.2014.05.016_bb0125","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.maturitas.2009.09.011","article-title":"Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate","volume":"64","author":"Munoz-Torres","year":"2009","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2014.05.016_bb0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.maturitas.2011.11.024","article-title":"Serum cathepsin K levels are not suitable to differentiate women with chronic bone disorders such as osteopenia and osteoporosis from healthy pre- and postmenopausal women","volume":"71","author":"Adolf","year":"2012","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2014.05.016_bb0135","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.clinbiochem.2013.04.012","article-title":"The development and characterization of an ELISA specifically detecting the active form of cathepsin K","volume":"46","author":"Sun","year":"2013","journal-title":"Clin Biochem"},{"key":"10.1016\/j.bone.2014.05.016_bb0140","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1124\/dmd.113.056580","article-title":"Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans","volume":"42","author":"Kassahun","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bone.2014.05.016_bb0145","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1210\/er.2007-0014","article-title":"RANKL and OPG regulation of bone remodeling in health and disease","volume":"29","author":"Kearns","year":"2008","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bone.2014.05.016_bb0150","doi-asserted-by":"crossref","first-page":"E1909","DOI":"10.1210\/jc.2012-1971","article-title":"Changes of serum soluble receptor activator for nuclear factor-\u03baB ligand after glucocorticoid therapy reflect regulation of its expression by osteoblasts","volume":"97","author":"Kaneko","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0155","doi-asserted-by":"crossref","first-page":"E1007","DOI":"10.1210\/jc.2012-3885","article-title":"Assessment of OPG\/RANK\/RANKL gene expression levels in peripheral blood mononuclear cells (PBMC) after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis","volume":"98","author":"Stuss","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0160","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1007\/s00198-011-1740-9","article-title":"Relationship between serum RANKL and RANKL in bone","volume":"22","author":"Findlay","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0165","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.devcel.2005.03.016","article-title":"Wnt\/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis","volume":"8","author":"Day","year":"2005","journal-title":"Dev Cell"},{"key":"10.1016\/j.bone.2014.05.016_bb0170","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2014.05.016_bb0175","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/sj.bjc.6603959","article-title":"Increased dickkopf-1 (Dkk-1) expression in breast cancer bone metastases","volume":"97","author":"Voorzanger-Rousselot","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bone.2014.05.016_bb0180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","article-title":"Dickkopf-1 is a master regulator of joint remodeling","volume":"13","author":"Diarra","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.bone.2014.05.016_bb0185","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1002\/art.22867","article-title":"Wnt signaling antagonists are potential prognostic biomarkers for the progression of radiographic hip osteoarthritis in elderly Caucasian women","volume":"56","author":"Lane","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.bone.2014.05.016_bb0190","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1136\/ard.2008.102350","article-title":"Opposite relationships between circulating Dkk-1 and cartilage breakdown in patients with rheumatoid arthritis and knee osteoarthritis","volume":"68","author":"Voorzanger-Rousselot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bone.2014.05.016_bb0195","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/jor.21260","article-title":"The role of Dkk1 in bone mass regulation: correlating serum Dkk1 expression with bone mineral density","volume":"29","author":"Butler","year":"2011","journal-title":"J Orthop Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0200","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1365-2265.2009.03728.x","article-title":"The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis","volume":"72","author":"Anastasilakis","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.bone.2014.05.016_bb0205","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bone.2013.08.016","article-title":"Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover","volume":"57","author":"Gifre","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.05.016_bb0210","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1210\/jc.2010-2552","article-title":"The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1","volume":"96","author":"Gatti","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0215","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/annrheumdis-2011-200216","article-title":"High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis","volume":"71","author":"Heiland","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bone.2014.05.016_bb0220","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1365-2141.2009.07587.x","article-title":"Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma","volume":"145","author":"Voorzanger-Rousselot","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bone.2014.05.016_bb0225","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s00223-003-0155-9","article-title":"Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate","volume":"74","author":"Grey","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0230","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1210\/en.2002-220347","article-title":"The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase","volume":"143","author":"Grey","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2014.05.016_bb0235","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/jcb.21915","article-title":"Sphingosine-1-phosphate acts as a developmental stage specific inhibitor of platelet-derived growth factor-induced chemotaxis of osteoblasts","volume":"105","author":"Roelofsen","year":"2008","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.bone.2014.05.016_bb0240","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1038\/sj.emboj.7601430","article-title":"Kim HH Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast\u2013osteoblast coupling","volume":"25","author":"Ryu","year":"2006","journal-title":"EMBO J"},{"key":"10.1016\/j.bone.2014.05.016_bb0245","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature07713","article-title":"Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis","volume":"458","author":"Ishii","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bone.2014.05.016_bb0250","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1084\/jem.20101474","article-title":"Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo","volume":"207","author":"Ishii","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.bone.2014.05.016_bb0255","doi-asserted-by":"crossref","first-page":"E1421","DOI":"10.1210\/jc.2012-1044","article-title":"Higher circulating sphingosine 1-phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans","volume":"97","author":"Lee","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0265","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1210\/jc.2012-2346","article-title":"Plasma sphingosine 1-phosphate levels and the risk of vertebral fracture in postmenopausal women","volume":"97","author":"Kim","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0270","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3109\/00016925509170789","article-title":"An uncommon familial systemic disease of the skeleton: hyperostosis corticalis generalisata familiaris","volume":"44","author":"Buchem","year":"1955","journal-title":"Acta Radiol"},{"key":"10.1016\/j.bone.2014.05.016_bb0275","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1399-0004.1984.tb00481.x","article-title":"The syndromic status of sclerosteosis and van Buchem disease","volume":"25","author":"Beighton","year":"1984","journal-title":"Clin Genet"},{"key":"10.1016\/j.bone.2014.05.016_bb0280","first-page":"505","article-title":"Cranial CT findings in sclerosteosis","volume":"7","author":"Hill","year":"1986","journal-title":"Am J Neuroradiol"},{"key":"10.1016\/j.bone.2014.05.016_bb0285","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1177\/0022034509338340","article-title":"Sclerostin in mineralized matrices and van Buchem disease","volume":"88","author":"Bezooijen","year":"2009","journal-title":"J Dent Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0290","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1359\/jbmr.080216","article-title":"Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength","volume":"23","author":"Li","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0295","doi-asserted-by":"crossref","first-page":"e25900","DOI":"10.1371\/journal.pone.0025900","article-title":"Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL dependent pathway","volume":"6","author":"Wijenayaka","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2014.05.016_bb0300","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/jbmr.1547","article-title":"Osteocyte RANKL: New insights into the control of bone remodeling","volume":"27","author":"Jinhu","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0305","doi-asserted-by":"crossref","first-page":"19883","DOI":"10.1074\/jbc.M413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical Wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2014.05.016_bb0310","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Semenov","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2014.05.016_bb0315","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2014.05.016_bb0320","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/jbmr.2092","article-title":"Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin in healthy postmenopausal women","volume":"29","author":"Womack","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0325","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.1210\/jc.2013-2113","article-title":"Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women","volume":"98","author":"Durosier","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0330","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00198-014-2635-3","article-title":"Comparison of two commercially available ELISAs for circulating sclerostin","volume":"25","author":"Costa","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0335","doi-asserted-by":"crossref","first-page":"5056","DOI":"10.1210\/jc.2010-0720","article-title":"Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women","volume":"95","author":"Drake","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0340","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1210\/jc.2013-2786","article-title":"Renal elimination of sclerostin increases with declining kidney function","volume":"99","author":"Cejka","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0345","first-page":"248","article-title":"Sclerostin levels during growth in children","volume":"99","author":"Kirmani","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0350","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1210\/jc.2009-2283","article-title":"Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women","volume":"95","author":"Mirza","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0355","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0360","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/jbmr.479","article-title":"Determinants of serum sclerostin in healthy pre- and postmenopausal women","volume":"26","author":"Ardawi","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0365","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Regulation of circulating sclerostin levels by sex steroids in women and in men","volume":"26","author":"M\u00f6dder","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0370","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/jbmr.1888","article-title":"Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study","volume":"28","author":"Szulc","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0375","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1210\/jc.2013-2106","article-title":"Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women","volume":"98","author":"Costa","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0380","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/jbmr.1929","article-title":"Sclerostin and bone strength in women in their 10th decade of life","volume":"28","author":"Thorson","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0385","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2265.2011.04315.x","article-title":"Serum sclerostin levels were positively correlated with fat mass and bone mineral density in Central South Chinese postmenopausal women","volume":"76","author":"Sheng","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.bone.2014.05.016_bb0390","doi-asserted-by":"crossref","first-page":"E1473","DOI":"10.1210\/jc.2012-1218","article-title":"Inoue S Association of circulating sclerostin levels with fat mass and metabolic disease\u2014Related markers in Japanese postmenopausal women","volume":"97","author":"Urano","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0395","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00198-013-2517-0","article-title":"Relative influence of heritability, environment and genetics on serum sclerostin","volume":"25","author":"Kuipers","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0400","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2011-3419","article-title":"Serum sclerostin and risk of hip fracture in older Caucasian women","volume":"97","author":"Arasu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0405","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1002\/jbmr.1718","article-title":"High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: The CEOR study","volume":"27","author":"Ardawi","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0410","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00198-012-1978-x","article-title":"Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study","volume":"24","author":"Garnero","year":"2013","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0415","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/jbmr.1823","article-title":"Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study","volume":"28","author":"Szulc","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0420","doi-asserted-by":"crossref","first-page":"775","DOI":"10.2337\/diab.44.7.775","article-title":"Bone loss and bone turnover in diabetes","volume":"44","author":"Krakauer","year":"1995","journal-title":"Diabetes"},{"key":"10.1016\/j.bone.2014.05.016_bb0425","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1210\/jc.2011-2958","article-title":"Circulating sclerostin levels and bone turnover in type 1 and type 2 Diabetes","volume":"97","author":"Gennari","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0430","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/jc.2011-2186","article-title":"Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus","volume":"97","author":"Garc\u00eda-Mart\u00edn","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0435","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.bone.2013.06.029","article-title":"Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes","volume":"56","author":"Ardawi","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.05.016_bb0440","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1210\/jc.2013-2143","article-title":"Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus","volume":"98","author":"Yamamoto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0445","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00198-011-1675-1","article-title":"Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women","volume":"23","author":"Chung","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0450","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bone.2011.11.028","article-title":"Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin","volume":"50","author":"Gatti","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.bone.2014.05.016_bb0455","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2012-4039","article-title":"Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal Osteoporosis","volume":"98","author":"Catalano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0460","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/jbmr.1681","article-title":"Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab","volume":"27","author":"Gatti","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0465","doi-asserted-by":"crossref","first-page":"E1848","DOI":"10.1210\/jc.2011-1534","article-title":"Acute decline in serum sclerostin in response to PTH infusion in healthy men","volume":"96","author":"Yu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0470","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00198-010-1525-6","article-title":"Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women\u2014the six-month effect of risedronate and teriparatide","volume":"23","author":"Polyzos","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2014.05.016_bb0475","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1210\/jc.2013-4105","article-title":"Teriparatide increases bone formation and bone mineral density in adult women with anorexia nervosa","volume":"99","author":"Fazeli","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2014.05.016_bb0480","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1172\/JCI18399","article-title":"FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting","volume":"112","author":"Riminucci","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2014.05.016_bb0485","doi-asserted-by":"crossref","first-page":"37419","DOI":"10.1074\/jbc.M304544200","article-title":"Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX","volume":"278","author":"Liu","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2014.05.016_bb0495","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0500","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1359\/jbmr.080220","article-title":"Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro","volume":"23","author":"Wang","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0505","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00467-012-2309-3","article-title":"FGF23 production by osteocytes","volume":"28","author":"Bonewald","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.bone.2014.05.016_bb0510","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/en.2003-1768","article-title":"Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha I collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis","volume":"145","author":"Larsson","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2014.05.016_bb0515","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrneph.2012.116","article-title":"The role of FGF23 in CKD-with or without Klotho","volume":"8","author":"Komaba","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.bone.2014.05.016_bb0520","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/jbmr.263","article-title":"Serum fibroblast growth factor\u201023 (FGF\u201023) and fracture risk in elderly men","volume":"26","author":"Mirza","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0525","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/jbmr.1985","article-title":"Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: the Osteoporotic Fractures in Men (MrOS) study","volume":"28","author":"Lane","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0530","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/nrendo.2011.234","article-title":"Micro RNA control of bone formation and homeostasis","volume":"8","author":"Lian","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.bone.2014.05.016_bb0535","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1074\/jbc.M805777200","article-title":"Impaired micro-RNA pathways diminish osteoclast differentiation and function","volume":"284","author":"Sugatani","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2014.05.016_bb0540","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11914-013-0143-6","article-title":"Micro RNA functions and dysfunctions in osteoporosis","volume":"11","author":"van Wijnen","year":"2013","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.bone.2014.05.016_bb0545","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nm.3026","article-title":"miR-214 targets ATF4 to inhibit bone formation","volume":"19","author":"Wang","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.bone.2014.05.016_bb0550","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0092-8674(04)00344-7","article-title":"ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin\u2013Lowry Syndrome","volume":"117","author":"Yang","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.bone.2014.05.016_bb0555","doi-asserted-by":"crossref","first-page":"e3148","DOI":"10.1371\/journal.pone.0003148","article-title":"Serum microRNAs are promising novel biomarkers","volume":"3","author":"Gilad","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2014.05.016_bb0560","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.bone.2014.05.016_bb0565","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/jbmr.1845","article-title":"MiR-148a regulates osteoclastogenesis by targeting V-maf musculoaponeurotic fibrosarcoma oncogene B","volume":"28","author":"Cheng","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0570","doi-asserted-by":"crossref","first-page":"e34641","DOI":"10.1371\/journal.pone.0034641","article-title":"MiR-133a in human circulating monocytes: a potential biomarker associated with postmenopausal osteoporosis","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2014.05.016_bb0575","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/jbmr.2032","article-title":"MiRNA 503 regulates osteoclastogenesis via targeting RANK","volume":"29","author":"Chen","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0580","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2175","article-title":"Five freely circulating miRNAs and bone tissue miRNA are associated with osteoporotic fractures","author":"Seeliger","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2014.05.016_bb0585","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2014-eular.1839","article-title":"Signature of circulating microRNAs in osteoarthritis","author":"Beyer","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328214001938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328214001938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T10:20:36Z","timestamp":1716805236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328214001938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":115,"alternative-id":["S8756328214001938"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2014.05.016","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New developments in biological markers of bone metabolism in osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2014.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}